ALMS Surges as Envudeucitinib Meets Goals in Plaque Psoriasis Studies [Yahoo! Finance]
Amgen Inc. (AMGN)
Last amgen inc. earnings: 4/30 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.amgen.com
Company Research
Source: Yahoo! Finance
ONWARD2 — which evaluated its pipeline candidate, envudeucitinib, for treating patients with moderate-to-severe plaque psoriasis, a chronic autoimmune skin disease. Both the ONWARD1 and ONWARD2 studies met all primary and secondary endpoints with high statistical significance in patients with moderate-to-severe plaque psoriasis. Treatment with envudeucitinib led to superior skin clearance versus placebo on the co-primary endpoints of Psoriasis Area and Severity Index (PASI) 75 and static Physician's Global Assessment (sPGA) 0/1 at week 16 in both studies. On average, in the ONWARD1 and ONWARD2 studies, 74% of patients achieved PASI 75 and 59% achieved sPGA 0/1, with responses improving over time. At week 24, across both studies, about 65% of patients achieved PASI 90 and more than 40% achieved PASI 100. Treatment with envudeucitinib was generally well tolerated through week 24 in both the ONWARD1 and ONWARD2 studies. Treatment with envudeucitinib also achieved superior skin cl
Show less
Read more
Impact Snapshot
Event Time:
AMGN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AMGN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AMGN alerts
High impacting Amgen Inc. news events
Weekly update
A roundup of the hottest topics
AMGN
News
- Amgen (NASDAQ:AMGN) was upgraded by analysts at UBS Group AG to a "strong-buy" rating.MarketBeat
- Should Amgen's (AMGN) Exclusive DISCO Oncology Deal Require Action From Investors? [Yahoo! Finance]Yahoo! Finance
- BioLab Holdings Announces Significant Team Growth Across Key Departments [Yahoo! Finance]Yahoo! Finance
- Amgen (NASDAQ:AMGN) had its price target raised by analysts at Truist Financial Corporation from $318.00 to $319.00. They now have a "hold" rating on the stock.MarketBeat
- AMGEN TO PRESENT AT THE 44TH ANNUAL J.P. MORGAN HEALTHCARE CONFERENCEPR Newswire
AMGN
Earnings
- 11/4/25 - Beat
AMGN
Sec Filings
- 11/21/25 - Form 4
- 11/20/25 - Form 144
- 11/13/25 - Form 4
- AMGN's page on the SEC website